Here are the DEF 14A proxy statements from Cryo-Cell International Inc. (CCEL) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCEL filings page.
Cryo-Cell International, Inc. (CCEL) is soliciting votes at its October 27, 2026 annual meeting on four director nominees—David I. Portnoy, Mark L. Portnoy, Harold D. Berger and Daniel Mizrahi—ratification of Wipfli LLP’s appointment for fiscal 2026, a non-binding advisory vote on named executive compensation, and other business. Holders of record on September 21, 2026 may vote one share on each matter; 8,062,650 common shares were outstanding on that date. The Board recommends “FOR” the nominees, auditor ratification and compensation resolution.
For fiscal 2025, reported total compensation was $1,618,516 for Co-CEO David I. Portnoy and $1,085,418 for Co-CEO Mark L. Portnoy. Cryo-Cell reported a net loss of $2.429 million in fiscal 2025, compared with net income of $402,000 in fiscal 2024. The say-on-pay vote is non-binding, and the Compensation Committee says it will consider the result in future compensation decisions. The ownership table reports 3,442,514 shares, or 39.93%, beneficially owned by current directors and executive officers as a group as of September 21, 2026.